Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Thionucleotides

abstract

  • Despite extensive data supporting a critical role for Bcl-2 in chemoresistance in SCLC, addition of oblimersen to a standard regimen for this disease did not improve any clinical outcome measure. Emerging data from several groups suggest that this lack of efficacy may be due to insufficient suppression of Bcl-2 in vivo. Additional evaluation of this agent in SCLC is not warranted.

publication date

  • February 20, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3715075

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.14.3461

PubMed ID

  • 18281659

Additional Document Info

start page

  • 870

end page

  • 6

volume

  • 26

number

  • 6